{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:24:38Z","timestamp":1693344278853},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T00:00:00Z","timestamp":1558656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00120-019-0953-y","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T17:38:54Z","timestamp":1558719534000},"page":"1185-1197","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Einsatz von Docetaxel oder Abirateron in Kombination mit einer Androgendeprivationstherapie beim metastasierten hormonnaiven Prostatakarzinom"],"prefix":"10.1007","volume":"58","author":[{"given":"P.","family":"Hammerer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Manka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,24]]},"reference":[{"key":"953_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.eururo.2017.10.028","volume":"73","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R (2018) Abiraterone or Docetaxel plus androgen deprivation in hormone-sensitive prostate cancer: more questions than answers. Eur Urol 73:845\u2013846","journal-title":"Eur Urol"},{"key":"953_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B et\u00a0al (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565\u2013573","journal-title":"Eur Urol"},{"key":"953_CR3","first-page":"75","volume":"9","author":"H Broder","year":"2008","unstructured":"Broder H, Gottlieb RA, Lepor NE (2008) Chemotherapy and cardiotoxicity. Rev Cardiovasc Med 9:75\u201383","journal-title":"Rev Cardiovasc Med"},{"key":"953_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657","author":"AH Bryce","year":"2018","unstructured":"Bryce AH, Chen YH, Liu G et\u00a0al (2018) Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial. J\u00a0Clin Oncol. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.75.3657","journal-title":"J Clin Oncol"},{"key":"953_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1080\/14656566.2017.1328056","volume":"18","author":"TN Clinton","year":"2017","unstructured":"Clinton TN, Woldu SL, Raj GV (2017) Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Expert Opin Pharmacother 18:825\u2013832","journal-title":"Expert Opin Pharmacother"},{"key":"953_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71:630\u2013642","journal-title":"Eur Urol"},{"key":"953_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","volume":"35","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Schally AV, Pinthus JH et al (2017) The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol 35:183\u2013191","journal-title":"Urol Oncol"},{"key":"953_CR8","volume-title":"Leitlinienprogrogramm Onkologie: Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Konsultatinosfassung, AWMF Registernummer: 043\/022OL","author":"Deutsche Krebsgesellschaft","year":"2017","unstructured":"Deutsche Krebsgesellschaft, Deusche Krebshilfe, Awmf (2017) Leitlinienprogrogramm Onkologie: Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Konsultatinosfassung, AWMF Registernummer: 043\/022OL. \n                    http:\/\/leitlinienprogrammonkologie.de\/Prostatakarzinom.58.0.html\n                    \n                  . Zugegriffen: 19. Jan. 2018"},{"key":"953_CR9","volume-title":"Leitlinienprogrogramm Onkologie: Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 4.0, AWMF Registernummer: 043\/022OL","author":"Deutsche Krebsgesellschaft","year":"2016","unstructured":"Deutsche Krebsgesellschaft, Deusche Krebshilfe, Awmf (2016) Leitlinienprogrogramm Onkologie: Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 4.0, AWMF Registernummer: 043\/022OL. \n                    http:\/\/leitlinienprogrammonkologie.de\/Prostatakarzinom.58.0.html\n                    \n                  . Zugegriffen: 2. Jan. 2018"},{"key":"953_CR10","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/jco.2015.33.15_suppl.5005","volume":"33","author":"E Efstathiou","year":"2015","unstructured":"Efstathiou E, Li W, Gormley M et al (2015) Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a\u00a0study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. J\u00a0Clin Oncol 33:5005\u20135005","journal-title":"J Clin Oncol"},{"key":"953_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1200\/JCO.2018.36.6_suppl.339","volume":"36","author":"A Eisenhardt","year":"2018","unstructured":"Eisenhardt A, Vosgerau S, Gedamke M et\u00a0al (2018) Cardiovascular comorbidities in German prostate cancer patients under androgen deprivation therapy: Results from a\u00a0retrospective analysis of patient data in urological outpatient centers. J\u00a0Clin Oncol 36:339","journal-title":"J Clin Oncol"},{"key":"953_CR12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174","author":"K Fizazi","year":"2018","unstructured":"Fizazi K, Feyerabend S, Matsubara N et al (2018) Longer term preplanned efficacy and safety analysis of abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-na\u00efve prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. J\u00a0Clin Oncol. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1704174","journal-title":"J Clin Oncol"},{"key":"953_CR13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus Prednisone in metastatic, castration-sensitive prostate cancer. N\u00a0Engl J Med 377:352\u2013360","journal-title":"N Engl J Med"},{"key":"953_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","volume":"73","author":"G Gravis","year":"2018","unstructured":"Gravis G, Boher JM, Chen YH et al (2018) Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early Docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol 73:847\u2013855","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"953_CR15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1200\/JCO.2018.36.6_suppl.354","volume":"36","author":"Helou","year":"2018","unstructured":"Helou et al (2018) Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: a pooled analysis of castration resistance-free survival and toxicity. J\u00a0Clin Oncol 36(6_suppl):354\u2013354","journal-title":"J Clin Oncol"},{"key":"953_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.urolonc.2014.06.018","volume":"32","author":"SN Hopmans","year":"2014","unstructured":"Hopmans SN, Duivenvoorden WC, Werstuck GH et\u00a0al (2014) GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a\u00a0preclinical mouse model. Urol Oncol 32:1126\u20131134","journal-title":"Urol Oncol"},{"key":"953_CR17","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.ejca.2015.06.106","volume":"51","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Verri E, Cossu Rocca M et al (2015) The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. Eur J Cancer 51:1970\u20131977","journal-title":"Eur J Cancer"},{"key":"953_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, De Bono JS, Spears MR et\u00a0al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N\u00a0Engl J Med 377:338\u2013351","journal-title":"N Engl J Med"},{"key":"953_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:1163\u20131177","journal-title":"Lancet"},{"key":"953_CR20","unstructured":"Janssen-Cilag International Nv Fachinformation Zytiga\u00ae 250\u202fmg Tabletten. Stand der Information: November 2017."},{"key":"953_CR21","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: a\u00a012-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531\u20131538","journal-title":"BJU Int"},{"key":"953_CR22","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.eururo.2013.12.063","volume":"66","author":"L Klotz","year":"2014","unstructured":"Klotz L, Miller K, Crawford ED et al (2014) Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol 66:1101\u20131108","journal-title":"Eur Urol"},{"key":"953_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-018-1238-9","author":"I Kushnir","year":"2018","unstructured":"Kushnir I, Koczka K, Ong M et\u00a0al (2018) The timing of docetaxel initiation in metastatic castrate sensitive prostate cancer and the rate of chemotherapy induced toxicity. J\u00a0Clin Oncol. \n                    https:\/\/doi.org\/10.1007\/s12032-018-1238-9","journal-title":"J Clin Oncol"},{"key":"953_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J\u00a0Clin Oncol 36:1080\u20131087","journal-title":"J Clin Oncol"},{"key":"953_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/acel.12331","volume":"14","author":"XM Liu","year":"2015","unstructured":"Liu XM, Chan HC, Ding GL et\u00a0al (2015) FSH regulates fat accumulation and redistribution in aging through the Galphai\/Ca(2+)\/CREB pathway. Aging Cell 14:409\u2013420","journal-title":"Aging Cell"},{"key":"953_CR26","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1200\/JCO.2018.36.15_suppl.5056","volume":"36","author":"GL Lu-Yao","year":"2018","unstructured":"Lu-Yao GL, Nightingale G, Nikita N et al (2018) Clinical outcomes following androgen receptor axis therapies (ARAT) among men with prostate cancer (PCa) having major cardiovascular diseases (CVDs) or extreme polypharmacy (EPP): a population based study. J\u00a0Clin Oncol 36:5056","journal-title":"J Clin Oncol"},{"key":"953_CR27","first-page":"e702","volume":"199","author":"D Margel","year":"2018","unstructured":"Margel D, Pe\u2019er A, Ber Y et al (2018) MP52-17 cardiovascular events and Biomarkers in A randomized trial comparing Lhrh agonist and antagonist among patients with advanced prostate cancer. J\u00a0Urol 199:e702","journal-title":"J Urol"},{"key":"953_CR28","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1200\/JCO.2018.78.0619","volume":"36","author":"MJ Morris","year":"2018","unstructured":"Morris MJ, Rumble RB, Basch E et al (2018) Optimizing anticancer therapy in metastatic non-castrate prostate cancer: American society of clinical oncology clinical practice guideline. J\u00a0Clin Oncol 36:1521\u20131539","journal-title":"J Clin Oncol"},{"key":"953_CR29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00120-017-0464-7","volume":"56","author":"C Ohlmann","year":"2017","unstructured":"Ohlmann C, Miller K, Gschwend J (2017) Androgendeprivation plus Abirateron\/Prednison beim metastasierten hormon-sensitiven Prostatakarzinom: gemeinsame Stellungnahme des Arbeitskreis Onkologie (AKO) und der Arbeitsgemeinschaft urologische Onkologie (AUO). Urologe 56:1185\u20131186","journal-title":"Urologe"},{"issue":"10162","key":"953_CR30","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD et\u00a0al (2018) Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE)investigators. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a\u00a0randomised controlled phase 3 trial. Lancet 392(10162):2353\u20132366","journal-title":"Lancet"},{"key":"953_CR31","unstructured":"Ratiopharm Gmbh Fachinformation Docetaxel-ratiopharm\u00ae 20\u202fmg\/ml Konzentrat zur Herstellung einer Infusionsl\u00f6sung. Stand der Information: Februar 2016."},{"key":"953_CR32","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/cncr.22933","volume":"110","author":"CS Saigal","year":"2007","unstructured":"Saigal CS, Gore JL, Krupski TL et\u00a0al (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493\u20131500","journal-title":"Cancer"},{"issue":"10","key":"953_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3238\/arztebl.2014.016","volume":"111","author":"A Schlitt","year":"2014","unstructured":"Schlitt A, Jordan K, Vordermark D, Schwamborn J, Langer T, Thomssen C (2014) Cardiotoxicity and oncological treatments. Dtsch Arztebl Int 111(10):161\u2013168. \n                    https:\/\/doi.org\/10.3238\/arztebl.2014.016","journal-title":"Dtsch Arztebl Int"},{"key":"953_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1464-410X.2009.08981.x","volume":"106","author":"FH Schroder","year":"2010","unstructured":"Schroder FH, Tombal B, Miller K et al (2010) Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a\u00a012-month, comparative, phase III study. BJU Int 106:182\u2013187","journal-title":"BJU Int"},{"key":"953_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1756287212461048","volume":"5","author":"ND Shore","year":"2013","unstructured":"Shore ND (2013) Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol 5:11\u201324","journal-title":"Ther Adv Urol"},{"key":"953_CR36","doi-asserted-by":"publisher","first-page":"TPS395","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS395","volume":"36","author":"SF Slovin","year":"2018","unstructured":"Slovin SF, Melloni C, Mansor-Lefebvre S et al (2018) A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist). J\u00a0Clin Oncol 36:TPS395","journal-title":"J Clin Oncol"},{"key":"953_CR37","volume-title":"Longitude and latitude: mapping new treatment directions in metastatic prostate cancer\u2014the evolving role of androgen receptor targeted therapy","author":"E Small","year":"2017","unstructured":"Small E (2017) Longitude and latitude: mapping new treatment directions in metastatic prostate cancer\u2014the evolving role of androgen receptor targeted therapy. ASCO Annual Meeting, Chicago"},{"key":"953_CR38","doi-asserted-by":"publisher","first-page":"720PD","DOI":"10.1093\/annonc\/mdw372.04","volume":"27","author":"C Sweeney","year":"2016","unstructured":"Sweeney C, Chen YH, Liu G et al (2016) Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone na\u00efve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Ann Oncol 27:720PD","journal-title":"Ann Oncol"},{"key":"953_CR39","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N\u00a0Engl J Med 373:737\u2013746","journal-title":"N Engl J Med"},{"key":"953_CR40","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","volume":"29","author":"MR Sydes","year":"2018","unstructured":"Sydes MR, Spears MR, Mason MD et al (2018) Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 29:1235\u20131248","journal-title":"Ann Oncol"},{"key":"953_CR41","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","volume":"32","author":"ME Taplin","year":"2014","unstructured":"Taplin ME, Montgomery B, Logothetis CJ et al (2014) Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a\u00a0randomized phase II neoadjuvant study. J\u00a0Clin Oncol 32:3705\u20133715","journal-title":"J Clin Oncol"},{"key":"953_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.eururo.2009.11.029","volume":"57","author":"B Tombal","year":"2010","unstructured":"Tombal B, Miller K, Boccon-Gibod L et al (2010) Additional analysis of the secondary end point of biochemical recurrence rate in a\u00a0phase 3 trial (CS21) comparing degarelix 80\u202fmg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 57:836\u2013842","journal-title":"Eur Urol"},{"key":"953_CR43","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00059-016-4422-8","volume":"41","author":"C Tschope","year":"2016","unstructured":"Tschope C, Kherad B, Spillmann F et al (2016) Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists. Herz 41:697\u2013705","journal-title":"Herz"},{"key":"953_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/pcan.2008.52","volume":"12","author":"UW Tunn","year":"2009","unstructured":"Tunn UW, Wiedey K (2009) Safety and clinical efficacy of a\u00a0new 6\u2011month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe. Prostate Cancer Prostatic Dis 12:83\u201387","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"953_CR45","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2017.10.002","volume":"73","author":"CJD Wallis","year":"2018","unstructured":"Wallis CJD, Klaassen Z, Bhindi B et al (2018) Comparison of Abiraterone acetate and Docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol 73:834\u2013844","journal-title":"Eur Urol"},{"key":"953_CR46","first-page":"3","volume":"86","author":"GM Walls","year":"2017","unstructured":"Walls GM, Lyon AR, Harbinson MT et\u00a0al (2017) Cardiotoxicity following cancer treatment. Ulster Med\u00a0J 86:3\u20139","journal-title":"Ulster Med J"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-019-0953-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-019-0953-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-019-0953-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T23:35:45Z","timestamp":1590190545000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-019-0953-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,24]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1007\/s00120-019-0953-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,24]]},"assertion":[{"value":"24 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Hammerer und L.\u00a0Manka geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}